Genentech gets FDA approval for Avastin to treat ovarian cancer
The FDA approval is based on results from the Phase III AURELIA trial that showed Avastin plus chemotherapy reduced the risk of disease worsening or death (progression-free survival)
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.
Initial results are being presented this weekend to clinicians convening during the American Heart Association meeting held in Chicago, including a meeting of the Association of Black Cardiologists.
This online proprietary platform: Emphasizes regulatory compliance of finished products Highlights quality assurance programs to prospective clients Showcases compliance to retailer programs The global economy and increased overseas